Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 18/20 | 0.64 |
| ▸ | CPB1 | P15086 | 9/20 | 0.64 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10583023 | 0.84 | CPB2 (0.64) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL6328167 | 0.84 | CPB2 (0.64) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL16508840 | 0.81 | CYP2C9 (0.44) | CPB2CPB1 | |
| SCHEMBL15601885 | 0.81 | CYP2C9 (0.44) | CPB2CPB1 | |
| SCHEMBL3839535 | 0.79 | CPB2 (1.00) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL6268747 | 0.79 | CPB2 (1.00) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL6499163 | 0.79 | CPB2 (0.69) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL19508749 | 0.78 | TRHDE (0.50) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL8345425 | 0.78 | CPB2 (0.55) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL20441237 | 0.78 | CPB2 (0.66) | CPB2CPB1KDM5AKDM5BCPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| US-9809616-B2 | Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer | EMORY UNIVERSITY (US) | 2017-11-07 | — | — | US | disclosed |
| US-9173893-B2 | Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections | COCRYSTAL PHARMA, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140235566-A1 | PYRIMIDINE NUCLEOSIDES AND THEIR MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS AND CANCER | EMORY UNIVERSITY (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-03-06 | — | — | US | disclosed |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235566-A1 | PYRIMIDINE NUCLEOSIDES AND THEIR MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS AND CANCER | PNP, TYMP, TK1 | CPB2 1266/4885CPB1 1455/4885KDM5A 2754/4885 |
| US-20140066395-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | CPB2 1610/4885CPB1 2213/4885KDM5A 2633/4885 |
| US-20120040924-A1 | PURINE NUCLEOSIDE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF CANCER AND VIRAL INFECTIONS | PNP, HAVCR2, TYMP | CPB2 1610/4885CPB1 2213/4885KDM5A 2633/4885 |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | CPB2 2184/4885CPB1 1960/4885KDM5A 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.